



Swansea University  
Prifysgol Abertawe



## Cronfa - Swansea University Open Access Repository

---

This is an author produced version of a paper published in:  
*Antimicrobial Agents and Chemotherapy*

Cronfa URL for this paper:

<http://cronfa.swan.ac.uk/Record/cronfa34176>

---

### Paper:

Warrilow, A., Parker, J., Price, C., Garvey, E., Hoekstra, W., Schotzinger, R., Wiederhold, N., Nes, W., Kelly, D. et. al. (2017). The Tetrazole VT-1161 Is a Potent Inhibitor of *Trichophyton rubrum* through its Inhibition of T. *rubrum* CYP51. *Antimicrobial Agents and Chemotherapy*, AAC.00333-17  
<http://dx.doi.org/10.1128/AAC.00333-17>

---

This item is brought to you by Swansea University. Any person downloading material is agreeing to abide by the terms of the repository licence. Copies of full text items may be used or reproduced in any format or medium, without prior permission for personal research or study, educational or non-commercial purposes only. The copyright for any work remains with the original author unless otherwise specified. The full-text must not be sold in any format or medium without the formal permission of the copyright holder.

Permission for multiple reproductions should be obtained from the original author.

Authors are personally responsible for adhering to copyright and publisher restrictions when uploading content to the repository.

<http://www.swansea.ac.uk/iss/researchsupport/cronfa-support/>

**The Tetrazole VT-1161 Is a Potent Inhibitor of  
*Trichophyton rubrum* through its Inhibition of *T. rubrum*  
CYP51**

**Andrew G.S. Warrilow,<sup>a</sup> Josie E. Parker,<sup>a</sup> Claire L. Price,<sup>a</sup> Edward P.  
Garvey,<sup>b</sup> William J Hoekstra,<sup>b</sup> Robert J. Schotzinger,<sup>b</sup> Nathan P.  
Wiederhold,<sup>c</sup> W. David Nes,<sup>d</sup> Diane E. Kelly,<sup>a</sup> Steven L. Kelly<sup>a</sup>**

Centre for Cytochrome P450 Biodiversity, Institute of Life Science, Swansea  
University Medical School, Swansea, Wales SA2 8PP, United Kingdom<sup>a</sup>; Viamet  
Pharmaceuticals Inc, Durham, North Carolina 27516 USA<sup>b</sup>; Fungus Testing  
Laboratory, Department of Pathology and South Texas Reference Laboratories,  
University of Texas Health Science Center at San Antonio, San Antonio, Texas  
78229 USA<sup>c</sup>; Department of Chemistry and Biochemistry, Texas Tech University,  
Lubbock, Texas 79409-1061, USA<sup>d</sup>

**Running title:** *VT-1161 inhibition of T. rubrum CYP51.*

**Keywords:** VT-1161, CYP51, *Trichophyton rubrum*, azole resistance, substrate  
specificity.

*VT-1161 inhibition of T. rubrum CYP51*

\*Corresponding author. Mailing address: Institute of Life Science, Swansea University Medical School, Swansea, Wales SA2 8PP, United Kingdom. Phone: +44 1792 292207 Fax: +44 1792 503430 Email: [s.l.kelly@swansea.ac.uk](mailto:s.l.kelly@swansea.ac.uk)

Prior to characterization of antifungal inhibitors that target this enzyme, *Trichophyton rubrum* CYP51 was expressed in *Escherichia coli*, purified and characterized. *T. rubrum* CYP51 bound lanosterol, obtusifoliol and eburicol with similar affinities ( $K_d$  values 22.7, 20.3 and 20.9  $\mu\text{M}$ ), but displayed substrate specificity insofar as only eburicol was demethylated in CYP51 reconstitution assays (turnover number  $1.55 \text{ min}^{-1}$ ,  $K_m$  value 2  $\mu\text{M}$ ). The investigational agent VT-1161 bound tightly to *T. rubrum* CYP51 ( $K_d = 242 \text{ nM}$ ) with similar affinity as clotrimazole, fluconazole, ketoconazole and voriconazole ( $K_d$  values 179, 173, 312, and 304 nM, respectively), and with lower affinity than itraconazole ( $K_d = 53 \text{ nM}$ ).  $\text{IC}_{50}$  determinations using 0.5  $\mu\text{M}$  CYP51 showed VT-1161 was a tight-binding inhibitor of *T. rubrum* CYP51 activity yielding an  $\text{IC}_{50}$  value of 0.14  $\mu\text{M}$  compared to 0.26, 0.4 and 0.6  $\mu\text{M}$  for itraconazole, fluconazole and ketoconazole, respectively. When tested against 34 clinical isolates, VT-1161 was a potent inhibitor of *T. rubrum* growth with  $\text{MIC}_{50}$ ,  $\text{MIC}_{90}$ , and geometric mean MIC values of  $\leq 0.03$ , 0.06, and 0.033  $\mu\text{g ml}^{-1}$ , respectively. With its selectivity versus human CYP51 and drug metabolizing CYPs having already been established, VT-1161 should prove safe and effective in combating *T. rubrum* infections in patients.

Infections of the ascomycete fungi *Trichophyton* spp. (e.g., onychomycosis or nail fungus, tinea pedis or athlete's foot, tinea corporis or ringworm) are some of the oldest human dermatological afflictions. Whilst not life-threatening, these infections can be of significant annoyance to the sufferer. *T. rubrum* is the most common dermatophyte infection in healthy individuals, accounting for up to 70% of skin infections (1) and up to 90% of nail infections (2, 3). Nail infections caused by *T. rubrum* affects around 10% of the population and are frequently intractable and prone to relapse upon termination of antifungal therapy (4, 5). *T. rubrum* infections of hair, skin and nails have increased over the past 70 years, especially in the elderly and in some countries also in children (6-8). Chronic skin infections caused by *T. rubrum* can become sites for secondary infection by other microorganisms, such as *Candida* spp., *Cryptococcus* spp., *Aspergillus* spp. and *Staphylococcus aureus*, which can become life-threatening in immunocompromised and immunosuppressed patients if the secondary infection becomes systemic (9-12).

Current therapeutic treatments against *T. rubrum* infection include azole antifungal agents, allylamines and thiocarbamates (all inhibiting ergosterol biosynthesis) administered orally or applied topically in creams and lotions. In chronic invasive and systemic fungal infections, especially amongst immunocompromised patients, amphotericin B (which disrupts fungal cell membranes) can be utilized intravenously. These antimycotic agents are most effective against the growing organism but are often ineffective against static phases of the organism, such as *T. rubrum* conidia, leading to reinfection unless

prolonged treatment regimens are adopted. Recently photodynamic treatments have been developed using photosensitizers in combination with UVA-1 radiation (340-400 nm) to kill both the mycelial form and conidia of *T. rubrum* (13) in topical dermal infections. The most commonly used antifungal agents against *T. rubrum* are ketoconazole, fluconazole, terbinafine and flucytosine (13). The prolonged treatment regimens often required have led to the emergence of azole resistant *T. rubrum* strains, especially against fluconazole (14-17).

In this study, we characterize the catalytic properties of recombinant *T. rubrum* CYP51 and compare the novel antifungal VT-1161 (18, 19) with clinical azole antifungal drugs in terms of potency and selectivity of binding to and inhibition of recombinant *T. rubrum* CYP51 and in inhibition of fungal growth in broth microdilution assays.

## RESULTS

**Expression and purification of Trub51.** Following heterologous expression in *E. coli*, Trub51 protein was extracted by sonication in 2% (wt/vol) sodium cholate which yielded 240 ( $\pm 80$ ) nmoles per liter culture as determined by carbon monoxide difference spectroscopy (20). Purification by Ni<sup>2+</sup>-NTA agarose chromatography resulted in an 84% recovery of native Trub51 protein yielding a stock 48  $\mu$ M solution after dialysis. SDS polyacrylamide gel electrophoresis confirmed the purity of the Ni<sup>2+</sup>-NTA agarose purified Trub51 to be greater than 90% when assessed by staining intensity.

**Spectral properties of Trub51.** The absolute spectrum of the resting oxidized form of Trub51 (Fig. 1A) was typical for a low-spin ferric cytochrome P450 enzyme (21, 22) with  $\alpha$ ,  $\beta$ , Soret ( $\gamma$ ) and  $\delta$  spectral bands at 567, 540, 420 and 361 nm. Reduced carbon monoxide difference spectra for Trub51 (Fig. 1B) gave the red-shifted heme Soret peak at 447 nm, characteristic of P450 enzymes, indicating the Trub51 protein was isolated in the native form. The formation of the reduced CO-P450 complex with Trub51 was rapid ( $t_{0.5} = 0.18 \pm 0.06$  min) although did not proceed to completion (hump visible at 422 nm).

**Sterol binding properties of Trub51.** Progressive titration of Trub51 with lanosterol, eburicol and obtusifoliol gave type I difference spectra with a peak at 388 nm and a trough at 421 nm (Fig. 2). Type I binding spectra occur when the substrate or another molecule displaces the water molecule coordinated as the sixth ligand to the low-spin hexa-coordinated heme prosthetic group causing the heme to adopt the high-spin penta-coordinated conformation (22). The intensity

( $\Delta A_{\max}$ ) of the type I binding spectra obtained with lanosterol was 7-fold lower than that obtained with eburicol and 3-fold lower than that obtained with obtusifoliol, suggesting that eburicol was the preferred substrate. However,  $K_d$  values of  $20.3 \pm 1.2 \mu\text{M}$ ,  $22.7 \pm 3.6 \mu\text{M}$  and  $20.9 \pm 0.3 \mu\text{M}$  were obtained for eburicol, lanosterol and obtusifoliol, respectively, indicating all three sterols bound with similar affinity.

**CYP51 reconstitution assays.** Trub51 did not catalyze the  $14\alpha$ -demethylation of lanosterol under the stated assay conditions. GC traces for TMS-derivatized CYP51 assay metabolites show lanosterol and eburicol emerging from the GC column after 35.65 and 38.25 minutes (Fig. 3A), whereas the  $14\alpha$ -demethylated product of eburicol emerged after 39.15 minutes. Confirmation of the identity of product 'P' was obtained by the mass fragmentation pattern (Fig. 3B) as TMS-derivatized C14-demethylated eburicol ( $M^+$  496). Trial Trub51 assays using  $50 \mu\text{M}$  obtusifoliol yielded no detectable metabolites (data not shown). This is only the second time that such strict substrate specificity has been observed for a fungal CYP51 enzyme, with *Mycosphaerella graminicola* CYP51 previously being shown to demethylate eburicol but not lanosterol *in vitro* (23).

Mild substrate inhibition was evident from the eburicol velocity curve obtained for Trub51 (Fig. 4) with calculated  $K_m$  and  $K_i$  values for eburicol of  $2 \mu\text{M}$  and  $225 \mu\text{M}$ , respectively. The maximum eburicol turnover number was  $1.55 \text{ min}^{-1}$ . The observed substrate inhibition suggests the presence of two distinct eburicol binding sites or binding orientations in Trub51 with one binding site /



orientation being catalytically productive whilst the other leads to the formation of an unproductive dead-end complex. However, no allosterism was observed in the eburicol type I difference binding spectra (Fig. 2B), suggesting eburicol binds in only one conformation that causes the displacement of the axial ligated heme water molecule responsible for the low- to high-spin state transition.

**CYP51 inhibitor binding properties of Trub51.** All five marketed imidazole and triazole antifungal agents and the novel tetrazole VT-1161 produced type II binding spectra (24) with Trub51 (Fig. 5). Ligand saturation curves (Fig. 6) confirmed azole binding was tight with the rearranged Morrison equation providing the best fit to the data (25, 26). Trub51 bound itraconazole the tightest with a  $K_d$  value of 53 ( $\pm 29$ ) nM whilst clotrimazole, fluconazole, voriconazole, ketoconazole and VT-1161 all apparently bound less tightly to Trub51 with similar  $K_d$  values of 179 ( $\pm 83$ ), 173 ( $\pm 53$ ), 304 ( $\pm 64$ ), 312 ( $\pm 36$ ) and 242 ( $\pm 99$ ), respectively.

**CYP51 inhibitor  $IC_{50}$  determinations.**  $IC_{50}$  determinations (Fig. 7) confirmed that fluconazole, itraconazole, ketoconazole and VT-1161 all inhibited *T. rubrum* CYP51 activity *in vitro*. VT-1161 caused the strongest inhibition ( $IC_{50}$  0.14  $\mu$ M), followed by itraconazole ( $IC_{50}$  0.26  $\mu$ M), then fluconazole and ketoconazole ( $IC_{50}$  values 0.4 and 0.6  $\mu$ M). Given the concentration of CYP51 used in this assay was 0.5  $\mu$ M, the expected  $IC_{50}$  value for an extremely tight-binding azole antifungal would be 0.25  $\mu$ M. Therefore, both VT-1161 and itraconazole bound extremely tightly to Trub51 whilst fluconazole and ketoconazole bound less tightly.

**CYP51 inhibitor MIC determinations.** MIC determinations (Table 1) confirmed the potency of VT-1161, as the MICs ranged from less than or equal to the lowest concentration tested ( $0.03 \mu\text{g ml}^{-1}$ ) to the highest MIC values of  $0.06 \mu\text{g ml}^{-1}$ . VT-1161's MIC<sub>50</sub>, MIC<sub>90</sub> and geometric mean values of  $\leq 0.03$ ,  $0.06$ , and  $0.033 \mu\text{g ml}^{-1}$  were slightly less than those for itraconazole ( $0.06$ ,  $0.06$ , and  $0.052 \mu\text{g ml}^{-1}$ , respectively), and both of these CYP51 inhibitors were significantly more potent than fluconazole ( $2$ ,  $16$ , and  $2.3 \mu\text{g ml}^{-1}$ , respectively). The GM MICs of VT-1161 and itraconazole were both significantly lower than that of fluconazole ( $p = 0.0018$  for both comparisons) but were not significantly different between each other.

**Phylogenetic comparison of fungal CYP51 enzymes.** The primary amino acid sequence of *T. rubrum* CYP51 contained all twenty-three conserved CYP51 residues previously identified by Lepesheva and Waterman (27) in addition to the conserved heme-binding cysteine residue (supplementary figure S1). The degree of conservation between the six-substrate recognition sites (SRSs) (28) varied (supplementary figure S1) with SRS-1 being the most conserved and SRS-6 the least conserved. Both *T. rubrum* and *M. graminicola* CYP51 enzymes can turnover eburicol but not lanosterol (this study; 23). *A. fumigatus* CYP51 isoenzymes A and B turnover both eburicol and lanosterol, albeit with a 4- to 7-fold preference for eburicol in terms of measured velocity using purified proteins (29) or more than an 18-fold preference for eburicol using membrane fractions. *C. albicans*, *C. neoformans* and *M. globosa* CYP51 enzymes, on the other hand, all readily turnover both eburicol and lanosterol (29-

31). Analysis of the amino acid sequences of the six SRSs between the seven fungal CYP51 enzymes did not identify any residue changes that could be directly linked to the change in substrate specificity observed in the *T. rubrum* and *M. graminicola* CYP51 enzymes.

## DISCUSSION

In preparation for studying antifungal inhibitors of this enzyme, we have fully characterized CYP51 from the most prevalent fungus causing human dermatophytosis, *Trichophyton rubrum*. The *T. rubrum* CYP51 (Trub51)  $K_d$  values for sterol substrates of 20 to 23  $\mu\text{M}$  were comparable with CYP51 enzymes from *Candida albicans* (11 to 28  $\mu\text{M}$ ) (32), *Mycosphaerella graminicola* (11 to 13  $\mu\text{M}$ ) (33), *Aspergillus fumigatus* CYP51B (9 to 23  $\mu\text{M}$ ) (29), *Cryptococcus neoformans* (12 to 21  $\mu\text{M}$ ) (30) and *Malassezia globosa* (23 to 32  $\mu\text{M}$ ) (31). However, the  $K_d$  values for lanosterol and eburicol with *Trypanosoma cruzi* CYP51 were lower at 1.9 and 1.2  $\mu\text{M}$  (34), and the  $K_d$  values for lanosterol with *H. sapiens* and *Mycobacterium tuberculosis* CYP51s were lower than Trub51 at 0.5 to 6  $\mu\text{M}$  (28, 35) and 1  $\mu\text{M}$  (21), respectively. However, Trub51 only catalyzed the 14 $\alpha$ -demethylation of eburicol and not that of lanosterol and obtusifoliol and mirrors that previously observed for *Mycosphaerella graminicola* CYP51 (23). This narrow substrate specificity is in contrast to the broad substrate specificity observed previously for CYP51 enzymes from *Candida albicans*, *Mycobacterium tuberculosis*, *Homo sapiens*, *Trypanosoma cruzi*, *Cryptococcus neoformans*, and *Malassezia globosa*, (30, 31, 36). Additional CYP51 enzymes that exhibit narrow substrate specificities include obtusifoliol-specific *Trypanosoma brucei* CYP51 and plant CYP51 enzymes such as *Sorgham bicolor* CYP51 (36), whilst *Aspergillus fumigatus* CYP51A and CYP51B isoenzymes have a strong preference for eburicol (29). The Trub51  $K_m$  for eburicol of 2  $\mu\text{M}$  was comparable to the substrate  $K_m$  values previously obtained for CYP51

enzymes from *C. albicans* and *Saccharomyces cerevisiae* (32, 37, 38), but was 5- to 30-fold lower than those determined for CYP51 enzymes from *Leishmania infantum*, *Homo sapiens*, *Mycosphaerella graminicola*, and *Malassezia globosa*, (23, 31, 36, 39). The strict eburicol substrate specificity of Trub51 could not be directly attributable to changes in the primary amino acid sequence of the six substrate recognition sites (28) relative to fungal CYP51 enzymes that readily demethylate both eburicol and lanosterol (supplementary figure S1).

It has been long recognized that fungal CYP51 inhibitors derive much of their binding potency through an “azole”/heme iron interaction (40), and that this binding can be directly measured spectroscopically (41). Therefore, as expected, Trub51 bound imidazole-based ketoconazole and clotrimazole, triazole-based fluconazole, voriconazole, and itraconazole, and the novel tetrazole-based VT-1161. Each compound displayed a type II binding spectra caused by the interaction of a heterocyclic ring nitrogen coordinating as the sixth ligand with the heme iron (24) to form the low-spin CYP51-azole complex resulting in a 'red-shift' of the heme Soret peak. Whereas, the specific nitrogen is known for the triazole inhibitors (N-4) (42) and imidazole inhibitors (N-3) (28), the interaction of VT-1161 with the heme ferric ion is through either the tetrazole's N-3 or N-4 nitrogen. The N-4 nitrogen was found to be more nucleophilic in heats of formation experiments (data not shown), and would therefore be the most likely atom to interact with the CYP51 heme iron.

The antifungal agents tested in this study bound Trub51 somewhat less tightly than to other fungal CYP51 enzymes, with the possible exception of

itraconazole. The relative differences observed in the  $K_d$  values, however, did not translate into equally large differences in  $IC_{50}$  values, with only a 4-fold increase in  $IC_{50}$  value being observed between VT-1161 and ketoconazole, and the  $IC_{50}$  for VT-1161 being numerically but not significantly lower than that for itraconazole. Therefore, for Trub51, the CYP51 reconstitution assay proved to be better at assessing CYP51-inhibitor potency than direct ligand binding to aqueous purified enzyme and was in agreement with the intrinsic antifungal potency measured in broth microdilution assays which ranked VT-1161 as the most potent *T. rubrum* inhibitor, closely followed by itraconazole, with fluconazole being the least potent (Table 1).

The performance of the drug candidate VT-1161 against *T. rubrum* CYP51 and *T. rubrum* itself was encouraging. We have shown biochemically that VT-1161 bound to the heme iron in the active site of Trub51 and strongly inhibited Trub51 activity through tight ligand binding. VT-1161 cellular potency against *T. rubrum* ranged from  $\leq 0.03$  to  $0.06 \mu\text{g/ml}$ , slightly more potent than for itraconazole ( $\leq 0.03$  to  $0.12 \mu\text{g/ml}$ ) and significantly more potent than for fluconazole ( $0.5$  to  $>64 \mu\text{g/ml}$ ). This MIC potency range for VT-1161 compares favorably to published MIC values for *T. rubrum* of  $0.03$  to  $256 \mu\text{g ml}^{-1}$  for fluconazole,  $0.008$  to  $0.25 \mu\text{g ml}^{-1}$  for itraconazole,  $0.06$  to  $2 \mu\text{g ml}^{-1}$  for ketoconazole and  $0.06$  to  $1 \mu\text{g ml}^{-1}$  for voriconazole (43-46). In addition, VT-1161 was as effective as itraconazole in treating *T. mentagrophytes*-induced dermatophytosis in guinea pig when treatments were orally administered daily and superior to itraconazole when administered weekly (47).

*VT-1161 inhibition of T. rubrum CYP51*

Equally important, the use of the tetrazole has allowed for the engineering of a more selective fungal CYP51 inhibitor relative to key human CYP enzymes (IC<sub>50</sub> values against CYPs 3A4, 2C9, 2C19, and 51 ranging from 65 to ~600 μM) (19). This greater selectivity coupled with at least maintaining if not improving antifungal potency should translate into a greater clinical therapeutic window, which in turn could allow for higher doses and possible greater efficacy. To this end, VT-1161 has achieved proof-of-concept efficacy (48) in a Phase 2a study in treatment of tinea pedis (NCT01891305), and has just completed a Phase 2b study in the treatment of onychomycosis (NCT02267356) with interim data demonstrating antifungal and clinical efficacy in conjunction with an excellent safety profile (49). Phase 3 studies are currently being planned to support registration approval of VT-1161 as a novel agent to treat onychomycosis.

## **MATERIALS AND METHODS**

**Construction of the pCWori<sup>+</sup>:Trub51 expression vector.** The *T. rubrum* CYP51 gene (Trub51 – UniProt accession number F2SHH3) was synthesized by Eurofins MWG Operon (Ebersberg, Germany) incorporating an *Nde*I restriction site at the 5' end and a *Hind*III restriction site at the 3' end of the gene cloned into pBSIISK<sup>+</sup> plasmid. In addition, the first eight amino acids were changed to 'MALLLAVF' (50) and a four-histidine extension (CATCACCATCAC) was inserted immediately before the stop codon. The Trub51 gene was excised by *Nde*I / *Hind*III restriction digestion followed by cloning into the pCWori<sup>+</sup> expression vector. Gene integrity was confirmed by DNA sequencing.

**Heterologous expression and purification of recombinant Trub51 protein.** The pCWori<sup>+</sup>:*Trub51* construct was transformed into competent DH5 $\alpha$  *E. coli* cells and expressed as previously described for *Candida albicans* CYP51 (32). Recombinant Trub51 protein was isolated according to the method of Arase *et al* (51) except that 2% (wt/vol) sodium cholate was used as sole detergent in the sonication buffer with the addition of 0.1 mM phenylmethylsulfonylfluoride. The solubilized Trub51 protein was purified by affinity chromatography using Ni<sup>2+</sup>-NTA agarose as previously described (21, 32) followed by dialysis against 20 mM Tris-HCl (pH 8.1) and 10% (wt/vol) glycerol. Protein purity was assessed by SDS polyacrylamide gel electrophoresis.

**Cytochrome P450 protein determinations.** Reduced carbon monoxide difference spectroscopy was performed (20) with carbon monoxide being passed through the cytochrome P450 solution prior to addition of sodium dithionite to the



sample cuvette (light path 10 mm). An extinction coefficient of  $91 \text{ mM}^{-1} \text{ cm}^{-1}$  (52) was used to calculate cytochrome P450 concentrations from the absorbance difference between 447 and 490 nm. Absolute spectra were determined between 700 and 300 nm (light path 4.5 mm). All spectral determinations were made using a Hitachi U-3310 UV/VIS spectrophotometer (San Jose, California).

**Sterol binding properties of Trub51.** Stock  $2 \text{ mg ml}^{-1}$  solutions of lanosterol, obtusifoliol and eburicol were prepared in 40% (wt/vol) (2-hydroxypropyl)- $\beta$ -cyclodextrin (HPCD). Sterol was progressively titrated against  $5 \text{ }\mu\text{M}$  Trub51 in a quartz semi-micro cuvette (light path 4.5 mm) with equivalent amounts of 40% (wt/vol) HPCD added to the reference cuvette which also contained  $5 \text{ }\mu\text{M}$  Trub51. The absorbance difference spectrum between 500 and 350 nm was determined after each incremental addition of sterol (up to  $75 \text{ }\mu\text{M}$ ). The sterol saturation curves were constructed from  $\Delta A_{388-421}$  derived from the difference spectra. The substrate dissociation constants ( $K_d$ ) were determined by non-linear regression (Levenberg-Marquardt algorithm) using the Michaelis-Menten equation.

**Azole binding properties of Trub51.** Binding clotrimazole, fluconazole, voriconazole, itraconazole, ketoconazole and the drug candidate VT-1161 to Trub51 was performed as previously described (32, 53) using 4.5 mm light-path quartz split-cuvettes. Stock  $0.05$ ,  $0.1$  and  $0.2 \text{ mg ml}^{-1}$  solutions of the azoles were prepared in dimethylsulfoxide and progressively titrated against  $2 \text{ }\mu\text{M}$  of Trub51 in  $0.1 \text{ M}$  Tris-HCl (pH 8.1) and 25% (wt/vol) glycerol. The difference spectra between 500 and 350 nm were determined after each incremental addition of

azole and binding saturation curves were constructed from  $\Delta A_{\text{peak-trough}}$  against azole concentration. The dissociation constants of the enzyme-azole complex ( $K_d$ ) were determined by non-linear regression (Levenberg-Marquardt algorithm) using a rearrangement of the Morrison equation for tight ligand binding (25, 26). Tight binding is normally observed where the  $K_d$  for a ligand is similar or lower than the concentration of the enzyme present (54).

**CYP51 reconstitution assays.** The reconstitution assays (34, 55) contained 0.5  $\mu\text{M}$  Trub51, 1  $\mu\text{M}$  *Aspergillus fumigatus* cytochrome P450 reductase isoenzyme 1 (AfCPR1 - UniProt accession number Q4WM67), 50  $\mu\text{M}$  sterol substrate, 50  $\mu\text{M}$  dilaurylphosphatidylcholine, 4% (wt/vol) HPCD, 0.4  $\text{mg ml}^{-1}$  isocitrate dehydrogenase, 25  $\text{mM}$  trisodium isocitrate, 50  $\text{mM}$  NaCl, 5  $\text{mM}$   $\text{MgCl}_2$  and 40  $\text{mM}$  MOPS (pH  $\sim 7.2$ ). Assay mixtures were incubated at 37°C prior to initiation with 4  $\text{mM}$   $\beta\text{-NADPHNa}_4$  followed by shaking at 37°C for 15 minutes. Sterol metabolites were recovered by extraction with ethyl acetate followed by derivatization with 0.1 ml *N,O*-bis(trimethylsilyl)trifluoroacetamide (BSTFA) : trimethylchlorosilane (TMCS) (99:1) and 0.3 ml anhydrous pyridine (2 h at 80°C) prior to analysis by gas chromatography mass spectrometry (GC/MS) (56). Trub51  $K_m$  value for eburicol was determined by varying the eburicol concentration in the CYP51 reconstitution assay between 3 and 100  $\mu\text{M}$  whilst maintaining a constant HPCD concentration of 4% (wt/vol). The single substrate inhibition equation [ $v = (V_{\text{max}} \cdot [\text{S}]) / \{K_m + [\text{S}] \cdot (1 + [\text{S}] / K_i)\}$ ] (57) was used to fit the data and to determine  $K_m$  and  $K_i$  values.

**Azole IC<sub>50</sub> determinations.** IC<sub>50</sub> determinations were performed using the CYP51 reconstitution assay detailed above in which various fluconazole, itraconazole, ketoconazole and VT-1161 concentrations in 2.5  $\mu$ l dimethylsulfoxide were added prior to incubation at 37°C and addition of  $\beta$ -NADPHNa<sub>4</sub>. The IC<sub>50</sub> assays contained 25  $\mu$ M eburicol, 0.5  $\mu$ M Trub51, 1  $\mu$ M AfCPR1 and 4 mM  $\beta$ -NADPHNa<sub>4</sub>.

**Minimum Inhibitory Concentration (MIC) determinations.** Drug preparations were prepared according to the recommendation outlined in the Clinical and Laboratory Standards Institute (CLSI) document M38-A2; this includes testing in RPMI-1640 with L-glutamine, with 0.165 M MOPS as the buffer (pH 7.0) and without bicarbonate, an inoculum size of  $1-5 \times 10^4$ , and incubation at 35°C for 96 hours. The MICs were measured visually as the lowest concentrations of each antifungal agent that resulted in an 80% reduction in turbidity as compared to a drug-free, growth control wells. Stock solutions of each agent were prepared in DMSO. Further dilutions were made in RPMI-1640, and the final concentration of DMSO was 1% (vol/vol). The final testing concentrations for VT-1161 and itraconazole ranged from 0.03-16  $\mu$ g ml<sup>-1</sup>, and for fluconazole from 0.125-64  $\mu$ g ml<sup>-1</sup>. *Trichophyton mentagrophytes* (ATCC-MYA-4439) served as the quality control organism, as recommended by M38-A2, was used on each day of testing. Results for this control isolate were within the appropriate range for each agent test. Thirty-four clinical *Trichophyton rubrum* isolates that were submitted to the Fungus Testing Laboratory (University of Texas Health Science Center at San Antonio, San Antonio, Texas) for antifungal

susceptibility testing and/or identification were used in this study. All strains were fresh clinical strains that had not been previously frozen. All MICs were measured once.

**Phylogenetic analysis of fungal CYP51 proteins.** Selected fungal CYP51 amino acid sequences were obtained from the UniProtKB database (<http://www.uniprot.org>) and were aligned using ClustalX software version 2.0.12 (<http://www.clustal.org/clustal2/>). The fungal sequences compared were *Aspergillus fumigatus* CYP51 isoenzyme A (UniProt accession number Q4WNT5), *Aspergillus fumigatus* CYP51 isoenzyme B (Q96W81), *Candida albicans* CYP51 (P10613), *Cryptococcus neoformans* CYP51 (Q5KQ65), *Malassezia globosa* CYP51 (A8Q3I7), *Mycosphaerella graminicola* CYP51 (Q5XWE5) and *Trichophyton rubrum* CYP51 (F2SHH3).

**Data analysis.** All ligand binding experiments were performed in triplicate and curve-fitting of data performed using the computer program QuantumSoft ProFit (version 6.1.12). Differences in geometric mean (GM) MIC values, calculated following log<sub>2</sub> transformation of individual MIC values, between VT-1161, itraconazole, and fluconazole were assessed for significance by ANOVA with Tukey's post-test for multiple comparisons. A p-value of <0.05 was considered statistically significant. For MIC values that were greater than the highest concentration tested, the next higher dilution value was used in the GM MIC calculations (e.g., fluconazole MIC >64 µg ml<sup>-1</sup>, 128 µg ml<sup>-1</sup> used). For MICs that were equal to or lower than the lowest concentration tested the lowest

concentration tested was used (e.g., VT-1161 or itraconazole MIC  $\leq$  0.03  $\mu\text{g ml}^{-1}$ , 0.03  $\mu\text{g ml}^{-1}$  used).

**Chemicals.** All chemicals, including clotrimazole, fluconazole, itraconazole, ketoconazole and voriconazole, were obtained from Sigma Chemical Company (Poole, UK). Growth media, sodium ampicillin, IPTG and 5-aminolevulinic acid were obtained from Foremedium Ltd (Hunstanton, UK). Ni<sup>2+</sup>-NTA agarose affinity chromatography matrix was obtained from Qiagen (Crawley, UK). VT-1161 was supplied by Viamet Pharmaceuticals, Inc. (Durham, North Carolina, USA).

## **ACKNOWLEDGMENTS**

We are grateful to the Engineering and Physical Sciences Research Council National Mass Spectrometry Service Centre at Swansea University and Mr. Marcus Hull for assistance in GC/MS analyses, and to Annette Fothergill at the UT Health Science Center San Antonio for assistance with *in vitro* susceptibility testing.

This work was in part supported by the European Regional Development Fund / Welsh Government funded BEACON research program (Swansea University), the National Science Foundation of the United States grant NSF-MCB-09020212 awarded to W. David Nes (Texas Tech University) and by Viamet Pharmaceuticals Inc (Durham, NC 27703, USA).

## REFERENCES

1. Weitzman I, Summerbell RC. 1995. The dermatophytes. Clin Microbiol Rev 8:240-259.
2. Summerbell RC, Kane J, Kraiden S. 1989. Onychomycosis, tinea pedis and tinea manuum caused by non-dermatophytic filamentous fungi. Mycoses 32:609-619.
3. Tietz HJ, Kunzelmann V, Schonian G. 1995. Changes in the fungal spectrum of dermatomycoses. Mycoses 38 Suppl 1:33-39.
4. Santos DA, Hamdan JS. 2006. In vitro antifungal oral drug and drug-combination activity against onychomycosis causative dermatophytes. Med Mycol 44:357-362.
5. Jackson CJ, Barton RC, Kelly SL, Evans EG. 2000. Strain identification of *Trichophyton rubrum* by specific amplification of subrepeat elements in the ribosomal DNA nontranscribed spacer. J Clin Microbiol 38:4527-4534.
6. Seebacher C, Bouchara J-P, Mignon B. 2008. Updates on the epidemiology of dermatophyte infections. Mycopathologia 166:335-352.
7. Adams C, Athanasoula E, Lee W, Mahmudova N, Vlahovic TC. 2015. Environmental and genetic factors on the development of Onychomycosis. J Fungi 1:211-216.
8. Oke OO, Onayemi O, Olasode OA, Omisore AG, Oninla OA. 2014. The prevalence and pattern of superficial fungal infections among school children in Ile-Ife, south-western Nigeria. Dermatol Res Pract Article ID:842917.

9. Rouzaud C, Hay R, Chosidow O, Dupin N, Puel A, Lortholary O, Lanternier F. 2016. Severe dermatophytosis and acquired or innate immunodeficiency: a review. *J Fungi* 2:4. doi:10.3390/jof2010004.
10. Mays SR, Bogle MA, Bodey GP. 2006. Cutaneous fungal infections in the oncology patient. *Am J Clin Dermatol* 7:31-43.
11. Virgili A, Zampino MA, Mantovani L. 2002. Fungal skin infections in organ transplant recipients. *Am J Clin Dermatol* 3:19-35.
12. Ilkit M, Durdu M. 2015. Tinea pedis: the etiology and global epidemiology of a common fungal infection. *Crit Rev Microbiol* 41:374-388.
13. Smijs TG, Pavel S. 2011. The susceptibility of dermatophytes to photodynamic treatment with special focus on *Trichophyton rubrum*. *Photochem Photobiol* 87:2-13.
14. Balkis MM, Leidich SD, Mukherjee PK, Ghannoum MA. 2002. Mechanisms of fungal resistance: an overview. *Drugs* 62:1025-1040.
15. Ishida K, de Mello JC, Cortez DA, Filho BP, Ueda-Nakamura T, Nakamura CV. 2006. Influence of tannins from *Stryphnodendron adstringens* on growth and virulence factors of *Candida albicans*. *J Antimicrob Chemother* 58:942-949.
16. Santos DA, Hamdan JS. 2007. In vitro activities of four antifungal drugs against *Trichophyton rubrum* isolates exhibiting resistance to fluconazole. *Mycoses* 50:286-9.



17. Kim D, Lim YR, Ohk SO, Kim BJ, Chun YJ. 2011. Functional expression and characterization of CYP51 from dandruff-causing *Malassezia globosa*. *FEMS Yeast Res* 11:80-87.
18. Hoekstra WJ, Garvey EP, Moore WR, Rafferty SW, Yates CM, Schotzinger RJ. 2014. Design and optimization of highly-selective fungal CYP51 inhibitors. *Bioorg Med Chem Lett* 24:3455-3458.
19. Warrilow AG, Hull CM, Parker JE, Garvey EP, Hoekstra WJ, Moore WR, Schotzinger RJ, Kelly DE, Kelly SL. 2014. The clinical candidate VT-1161 is a highly potent inhibitor of *Candida albicans* CYP51 but fails to bind the human enzyme. *Antimicrob Agents Chemother* 58:7121-7127.
20. Estabrook RW, Peterson, J.A., Baron, J., Hildebrandt, A.G. 1972. The spectrophotometric measurement of turbid suspensions of cytochromes associated with drug metabolism., vol 2. Appleton-Century-Crofts, New York, USA.
21. Bellamine A, Mangla AT, Nes WD, Waterman MR. 1999. Characterization and catalytic properties of the sterol 14 $\alpha$ -demethylase from *Mycobacterium tuberculosis*. *Proc Natl Acad Sci USA* 96:8937-8942.
22. Jefcoate CR. 1978. Measurement of substrate and inhibitor binding to microsomal cytochrome P-450 by optical-difference spectroscopy. *Methods Enzymol* 52:258-279.
23. Price CL, Warrilow AG, Parker JE, Mullins JG, Nes WD, Kelly DE, Kelly SL. 2015. Novel substrate specificity and temperature-sensitive activity of

- Mycosphaerella graminicola* CYP51 supported by the native NADPH cytochrome P450 reductase. *Appl Environ Microbiol* 81:3379-3386.
24. Jefcoate CR, Gaylor JL, Calabrese RL. 1969. Ligand interactions with cytochrome P-450. I. Binding of primary amines. *Biochemistry* 8:3455-3463.
  25. Lutz JD, Dixit V, Yeung CK, Dickmann LJ, Zelter A, Thatcher JE, Nelson WL, Isoherranen N. 2009. Expression and functional characterization of cytochrome P450 26A1, a retinoic acid hydroxylase. *Biochem Pharmacol* 77:258-268.
  26. Morrison JF. 1969. Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors. *Biochim Biophys Acta* 185:269-286.
  27. Lepesheva GI, Waterman MR. 2011. Structural basis for conservation in the CYP51 family. *Biochim Biophys Acta* 1814:88-93.
  28. Strushkevich N, Usanov SA, Park HW. 2010. Structural basis of human CYP51 inhibition by antifungal azoles. *J Mol Biol* 397:1067-1078.
  29. Warrilow AG, Parker JE, Price CL, Nes WD, Kelly SL, Kelly DE. 2015. *In vitro* biochemical study of CYP51-mediated azole resistance in *Aspergillus fumigatus*. *Antimicrob Agents Chemother* 59:7771-7778.
  30. Warrilow AG, Parker JE, Price CL, Nes WD, Garvey EP, Hoekstra WJ, Schotzinger RJ, Kelly DE, Kelly SL. 2016. The investigational drug VT-1129 is a highly potent inhibitor of *Cryptococcus species* CYP51 but only

- weakly inhibits the human enzyme. *Antimicrob Agents Chemother* 60:4530-4538.
31. Warrilow AG, Price CL, Parker JE, Rolley NJ, Smyrniotis CJ, Hughes DD, Thoss V, Nes WD, Kelly DE, Holman TR, Kelly SL. 2016. Azole antifungal sensitivity of sterol 14 $\alpha$ -demethylase (CYP51) and CYP5218 from *Malassezia globosa*. *Sci Rep* 6:27690.
  32. Warrilow AG, Martel CM, Parker JE, Melo N, Lamb DC, Nes WD, Kelly DE, Kelly SL. 2010. Azole binding properties of *Candida albicans* sterol 14 $\alpha$ -demethylase (CaCYP51). *Antimicrob Agents Chemother* 54:4235-4245.
  33. Parker JE, Warrilow AG, Cools HJ, Martel CM, Nes WD, Fraaije BA, Lucas JA, Kelly DE, Kelly SL. 2011. Mechanism of binding of prothioconazole to *Mycosphaerella graminicola* CYP51 differs from that of other azole antifungals. *Appl Environ Microbiol* 77:1460-1465.
  34. Lepesheva GI, Zaitseva NG, Nes WD, Zhou W, Arase M, Liu J, Hill GC, Waterman MR. 2006. CYP51 from *Trypanosoma cruzi*: a phyla-specific residue in the B' helix defines substrate preferences of sterol 14 $\alpha$ -demethylase. *J Biol Chem* 281:3577-3585.
  35. Lepesheva GI, Nes WD, Zhou W, Hill GC, Waterman MR. 2004. CYP51 from *Trypanosoma brucei* is obtusifoliol-specific. *Biochemistry* 43:10789-10799.
  36. Hargrove TY, Wawrzak Z, Liu J, Nes WD, Waterman MR, Lepesheva GI. 2011. Substrate preferences and catalytic parameters determined by

- structural characteristics of sterol 14 $\alpha$ -demethylase (CYP51) from *Leishmania infantum*. J Biol Chem 286:26838-26848.
37. Trösken ER, Adamska M, Arand M, Zarn JA, Patten C, Völkel W, Lutz WK. 2006. Comparison of lanosterol-14 $\alpha$ -demethylase (CYP51) of human and *Candida albicans* for inhibition by different antifungal. Toxicology 228:24-32.
  38. Kitahama Y, Nakamura M, Yoshida Y, Aoyama Y. 2009. The construction and characterization of self-sufficient lanosterol 14-demethylase fusion proteins consisting of yeast CYP51 and its reductase. Biol Pharm Bull 32:558-563.
  39. Ekins S, Mankowski DC, Hoover DJ, Lawton MP, Treadway JL, Harwood HJ, Jr. 2007. Three-dimensional quantitative structure-activity relationship analysis of human CYP51 inhibitors. Drug Metab Dispos 35:493-500.
  40. Yoshida Y. 1988. Cytochrome P450 of fungi: primary target for azole antifungal agents. Curr Top Med Mycol 2:388-418.
  41. Yoshida Y, Aoyama Y. 1987. Interaction of azole antifungal agents with cytochrome P-450<sub>14DM</sub> purified from *Saccharomyces cerevisiae* microsomes. Biochem Pharmacol 36:229-235.
  42. Chen CK, Leung SS, Guilbert C, Jacobson MP, McKerrow JH, Podust LM. 2010. Structural characterization of CYP51 from *Trypanosoma cruzi* and *Trypanosoma brucei* bound to the antifungal drugs posaconazole and fluconazole. PLoS Negl Trop Dis 4:e651.

43. Barros MES, Santos DA, Hamdan JS. 2006. *In vitro* methods for antifungal susceptibility testing of *Trichophyton spp.* Mycol Res 110:1355-1360.
44. Barros MES, Santos DA, Hamdan JS. 2007. Antifungal susceptibility testing of *Trichophyton rubrum* by E-test. Arch of Dermatol Res 299:107-109.
45. Sarifakioglu E, Seckin D, Demirbilek M, Can F. 2007. *In vitro* antifungal susceptibility patterns of dermatophyte strains causing tinea unguium. Clin Exp Dermatol 32:675-679.
46. Wang L, Yang W, Wang K, Zhu J, Shen F, Hu Y. 2012. Synthesis and biological evaluation of vinyl ether-containing azole derivatives as inhibitors of *Trichophyton rubrum*. Bioorg Medicinal Chem Lett 22:4887-4890.
47. Garvey EP, Hoekstra WJ, Moore WR, Schotzinger RJ, Long L, Ghannoum MA. 2015. VT-1161 dosed once daily or once weekly exhibits potent efficacy in treatment of dermatophytosis in a guinea pig model. Antimicrob Agents Chemother 59:1992-1997.
48. Degenhardt T, Pollak R, Jones T, Jarratt M, Brandt S, Schotzinger R. 2015. Efficacy and Safety of Oral VT-1161, a Novel and Selective Inhibitor of Fungal CYP51, in a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study (NCT01891305) in Patients with Moderate-to-Severe Interdigital Tinea Pedis. American Podiatric Medical Association 2015 Annual Meeting, Orlando, FL.

49. Tavakkol A, Pollak R, Reyzelman A, Weisfeld M, Curelop A, Handelsman C, Brand S, Degenhardt T, Schotzinger R. 2016. A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Four Oral Dosing Regimens of VT-1161 in the Treatment of Patients with Moderate-Severe Toenail Onychomycosis (RENOVATE): Results of a Planned Week 24 Interim Analysis. American Podiatric Medical Association 2016 Annual Meeting, Philadelphia, PA.
50. Barnes HJ, Arlotto MP, Waterman MR. 1991. Expression and enzymatic activity of recombinant cytochrome P450 17  $\alpha$ -hydroxylase in *Escherichia coli*. Proc Natl Acad Sci USA 88:5597-601.
51. Arase M, Waterman MR, Kagawa N. 2006. Purification and characterization of bovine steroid 21-hydroxylase (P450c21) efficiently expressed in *Escherichia coli*. Biochem Biophys Res Commun 344:400-405.
52. Omura T, Sato R. 1964. The Carbon Monoxide-Binding Pigment of Liver Microsomes. II. Solubilization, Purification, and Properties. J Biol Chem 239:2379-2385.
53. Lamb DC, Kelly DE, Waterman MR, Stromstedt M, Rozman D, Kelly SL. 1999. Characteristics of the heterologously expressed human lanosterol 14 $\alpha$ -demethylase (other names: P45014DM, CYP51, P45051) and inhibition of the purified human and *Candida albicans* CYP51 with azole antifungal agents. Yeast 15:755-763.

54. Copeland RA. 2005. Evaluation of enzyme inhibitors in drug discovery: a guide for medicinal chemists and pharmacologists. pp 178-213. Wiley-Interscience, New York.
55. Lepesheva GI, Ott RD, Hargrove TY, Kleshchenko YY, Schuster I, Nes WD, Hill GC, Villalta F, Waterman MR. 2007. Sterol 14 $\alpha$ -demethylase as a potential target for antitrypanosomal therapy: enzyme inhibition and parasite cell growth. *Chem Biol* 14:1283-1293.
56. Parker JE, Warrilow AG, Cools HJ, Fraaije BA, Lucas JA, Rigdova K, Griffiths WJ, Kelly DE, Kelly SL. 2013. Prothioconazole and prothioconazole-desthio activities against *Candida albicans* sterol 14 $\alpha$ -demethylase. *Appl Environ Microbiol* 79:1639-1645.
57. Copeland RA. 2000. Enzymes: a practical introduction to structure, mechanism and data analysis. (2 edn), p137, Wiley-VCH Inc, New York, USA. ISBN: 0-471-35929-7.

*VT-1161 inhibition of T. rubrum CYP51*

Table 1. MICs of VT-1161, itraconazole, and fluconazole against 34 clinical isolates of *T. rubrum*.

Drug	MIC ( $\mu\text{g ml}^{-1}$ )			
	50%	90%	Geometric mean	Range
VT-1161	$\leq 0.03$	0.06	0.033	$\leq 0.03 - 0.06$
Itraconazole	0.06	0.06	0.052	$\leq 0.03 - 0.12$
Fluconazole	2	16	2.3	0.5 - >64






FIG. 1. *Spectral characteristics of Trub51.* Absolute spectra (A) were determined using 3  $\mu$ M purified Trub51 in the oxidised resting state. Reduced carbon monoxide difference spectra (B) were determined using 3  $\mu$ M purified Trub51 with sequential measurements made every 45 seconds.




FIG. 2. Sterol binding properties of *Trub51*. Absorbance difference spectra (A) were measured during the progressive titration of 5  $\mu\text{M}$  *Trub51* with lanosterol, eburicol and obtusifoliol. Saturation curves (B) for lanosterol (filled circles), eburicol (hollow circles) and obtusifoliol (crosses) were constructed from the absorbance difference  $\Delta A_{388-421}$  of the type I difference spectra observed. Sterol binding data were fitted using the Michaelis-Menten equation.




FIG. 3. GC/MS analysis of *Trub51* reconstitution assay metabolites. GC traces (A) for *Trub51* reconstitution assays (37°C, 15 min) using lanosterol and eburicol as substrates are shown. In addition the mass fragmentation pattern (B) for the TMS-derivatized C14-demethylated eburicol ( $M^+$  496 – 'P') product is shown. Abundance is expressed in units of one thousand (K).




FIG. 4.  $K_m$  determination for eburicol. A velocity curve was constructed for eburicol with Trub51 using the CYP51 reconstitution assay (34, 55). The single substrate inhibition equation [ $v = (V_{max} \cdot [S]) / \{K_m + [S] \cdot (1 + [S]/K_i)\}$ ] (57) was used to fit the velocity curve. Mean values from three replicates and the associated standard deviation bars are shown.




FIG. 5. Type II azole binding spectra for *Trub51*. Clotrimazole, fluconazole, voriconazole, itraconazole, ketoconazole and VT-1161 were progressively titrated against 2  $\mu$ M CYP51 protein with the difference spectra determined after each addition of azole. The resultant type II difference spectra obtained for each azole are shown. Each experiment was performed in triplicate although only one replicate is shown.




FIG. 6. Azole binding saturation curves for *Trub51*. Saturation curves were constructed from the absorbance difference  $\Delta A_{\text{peak-trough}}$  of the type II difference spectra (Fig. 5) for clotrimazole (circles), fluconazole (squares), voriconazole (triangles), itraconazole (diamonds), ketoconazole (asterisks) and VT-1161 (crosses). A rearrangement of the Morrison equation (25) was used to fit the tight ligand binding observed. Each experiment was performed in triplicate although only one replicate is shown.




FIG. 7.  $IC_{50}$  determinations for antifungal agents. CYP51 reconstitution assays were performed using a CYP51:AfCPR ratio of 1:2 for 0.5  $\mu$ M Trub51 with 25  $\mu$ M eburicol as substrate at varying fluconazole (filled circles) itraconazole (hollow circles), ketoconazole (bullets) and VT-1161 (crosses) concentrations from 0 and 8  $\mu$ M. Mean relative velocity values are shown along with the associated standard deviation values. Relative velocities of 1.00 were equivalent to velocities of 1.55  $\text{min}^{-1}$ .

VT-1161 inhibition of *T. rubrum* CYP51

	10	20	30	40	50	60
Af51B	..... .....	..... .....	..... .....	..... .....	..... .....	..... .....
Trub51	-----MG	LIAFILDGIC	KHCSTQSTWV	LVGIGLLSIL	AVSVIINVLO	QLLFFK--NPH
Mgram51	-----MG	LLADIVSRFC	ENCSTLSTAA	LVASAISAFI	VLSIVINVLO	QLLFRG--DPT
Af51A	-----	LLQEVLQAQFD	AQFGQTSLWK	LVGLGFLAFS	TLAILLNVLS	QLLFRG-KLS
Cneo51	MSAIIPQVQO	LLGQVAQFFP	PWFAALPTSL	KVAIAVVGIP	ALIIGLNVFQ	QLCLPR-RKD
Mglob51	-----	MLQEIG-AWP	VWQQALT---	----FLVGGL	ALIVGINVLV	QVLVPR-NKS
Calb51	-----MA	IVETVIDGIN	YFLSLSVT--	---QQISILL	GVPFVYNLVW	QYLYSL-RKD
ClustalX					. ** *	
	70	80	90	100	110	120
Af51B	..... .....	..... .....	..... .....	..... .....	..... .....	..... .....
Trub51	EPVVVFWHWP	FIGSTISYGI	DPYKFFDCCR	AKYGDIFTFI	LLGKKTIVYL	GTKGNDFILN
Mgram51	KPPVVFWHWP	IIGSTISYGI	DPYKFFDDCK	EKYGDIFTFI	LLGKKTIVFL	GTKGNDFILN
Af51A	DPPLVFWHWP	FIGSTITYGI	DPYKFFFCR	EKYGDVFTFI	LLGKKTIVCL	GTKGNDFILN
Cneo51	EPPMVFWHWP	YLGSTISYGI	DPYKFFACR	EKYGDIFTFI	LLGQKTIVYL	GVQNEFILN
Mglob51	LPPVVPHYIP	WFGSAAYYGE	DPYKFLFECR	DKYGDIFTFI	LMGRRITVAL	GPKGNLNLG
Calb51	LPPMVFWHWP	VVGSAITYGM	DPYRFFNCR	EKYGDVFTFK	LFGRNVIVAL	GPKGSNLVFN
ClustalX	.*:*.:.*	.*: **	:**.*: *	:*	****:*:*	*:*: ** * * : * : : .
	130	140	150	160	170	180
		<u>SRS-1</u>				
Af51B	GKLRDVCAE	<b>E VYSPLTTPVF</b>	<b>GRHVYDPCN</b>	AKLMEQKKFV	KYGLTSDALR	SYVPLITDE <b>V</b>
Trub51	GKLRDVCAE	<b>D VYSPLTTPVF</b>	<b>GRHVYDPCN</b>	SKLMEQKKFV	KFGLTSEALR	SYVTLITK <b>E</b> V
Mgram51	GKLRDVNAE	<b>E IYSPLTTPVF</b>	<b>GKDVVYDPCN</b>	SKLMEQKKFV	KYGLTTSALQ	SYVTLIAA <b>E</b> T
Af51A	GKLRDVNAE	<b>E VYSPLTTPVF</b>	<b>GSDVVYDPCN</b>	SKLMEQKKFI	KYGLTQSALE	SHVPLIEK <b>E</b> V
Cneo51	GKISQVSAE	<b>E AYTHLTPVF</b>	<b>GKGVVYDPCN</b>	EMLMQKKFI	KSGLTTESLQ	SYPPMIT <b>S</b> EC
Mglob51	GRLTQVSAE	<b>E AYTSLTPVF</b>	<b>GKGVVYDPCN</b>	AVLMEQKRFV	KSGLSMENFR	MYVTQIES <b>E</b> V
Calb51	AKLSDVSAE	<b>E AYKHLTPVF</b>	<b>GKGVYDPCN</b>	SRLMEQKKFA	KFALTTDSFK	RYVPKIRE <b>E</b> I
ClustalX	.:.* **:	*. *****	* *:* **	****:*:	*.*: . : .	: . * *
	190	200	210	220	230	240
						<u>SRS-2</u>
Af51B	ESFVKNS---	PAFQG--HKG	VFDVCKTIAE	ITIIY <b>TASRSL</b>	QGKEVRSKFD	STFAE <b>LYHNL</b>
Trub51	EQFFESS---	PIFKG--DSG	VFNVSVMMAE	ITIIY <b>TASRSL</b>	QGKEVRGKFD	SSF <b>AE</b> LYSD <b>L</b>
Mgram51	RQFFDRNNPH	KKFAS--TSG	TIDLPPALAE	LTIY <b>TASRSL</b>	QGKEVREGFD	SSFAD <b>LYHYL</b>
Af51A	LDYLRDS---	PNFQG--SSG	RVDISAAMAE	ITIF <b>TAARAL</b>	QGQEVRSKLT	AEFAD <b>LYHDL</b>
Cneo51	EDFFTKEVGI	SPQKP---SA	TLDLLKAMSE	LIIL <b>TASRTL</b>	QGKEVRESLN	GQFAK <b>YYEDL</b>
Mglob51	KDFINNDAAF	LPLQKGATSV	TVDIFNVFSE	ITIL <b>TASRTL</b>	QGKEVRESLD	KTF <b>AK</b> LY <b>HDL</b>
Calb51	LNyFVTDESf	KLKEK--THG	VANVMKTQPE	ITIF <b>TASRSL</b>	FGDEMRRIFD	RSFA <b>Q</b> LYSD <b>L</b>
ClustalX	.: .		: . . *	: * ****:	*.*: :	** * *
	250	260	270	280	290	300
		<u>SRS-3</u>				
Af51B	<b>DMGF</b> FAPINFM	LPWAPLPH <b>NR</b>	<b>KRDAAQR</b> KL <b>T</b>	ETymeIIKAR	RQAGSKKDSE	-DMVWNLMS <b>C</b>
Trub51	<b>DMGF</b> AAINFM	FPWFPPH <b>NR</b>	<b>KRDAAQR</b> K <b>MA</b>	QVYTDIIRQR	RAAGGEKDSE	-DMVWNLMS <b>S</b>
Mgram51	<b>DMGF</b> TPINFM	LPWAPLPQ <b>NR</b>	<b>RRDYA</b> Q <b>KKMS</b>	ETyMSIIQKR	RESKTGEHEE	-DMIHNL <b>M</b> Q <b>C</b>
Af51A	<b>DKGF</b> TPINFM	LPWAPLPH <b>NK</b>	<b>KRDAAH</b> AR <b>M</b>	SIYVDIITQR	RLDGEKDSQK	SDMIWNL <b>M</b> NC
Cneo51	<b>DGGF</b> TPINFM	FPNLPLP <b>SYK</b>	<b>RRDEA</b> Q <b>KAMS</b>	DFYLKIMENR	RK-GESD-HE	HDMIENL <b>Q</b> SC
Mglob51	<b>DSGF</b> TPINFM	IPNLPLP <b>NNF</b>	<b>RRDRA</b> Q <b>RLMS</b>	DFYLGIIKKR	RE-GNTEGTE	HDMISAL <b>M</b> EQ
Calb51	<b>DKGF</b> TPINFM	FPNLPLPH <b>YW</b>	<b>RRDAA</b> Q <b>KKIS</b>	ATYMKEIKSR	RERGDIDPNR	DLIDSL <b>L</b> I <b>H</b> S
ClustalX	* ** : : **:	* * : *	: ** * : :	* : * *	. .	: *



VT-1161 inhibition of *T. rubrum* CYP51

```

          310          320          330          340          350          360
      ....|....| .. SRS-4 ....|....| ....|....| ....|....|
Af51B  VYKNGTPVPD EEIAHMMIAL LMAQQHSSSS TASWIVLRLA TRPDIMEELY QEQIRVLG-S
Trub51 VYKNGTPIPD IEVAHMMIAL LMAQQHSSSS TGSWIVLRLA SRPDILEELY EEQKRVLG-E
Mgram51 KYKDGNAIPD KEIAHMMIAL LMAQQHSSSA TESWITLRLA SRPDIQDELL QEQKMDLG-V
Af51A  TYKNGQQVPD KEIAHMMITL LMAQQHSSSS ISAWIMLRLA SQPKVLEELY QEQLANLGA
Cneo51  KYRNGVPLSD RDIAHIMIAL LMAQQHTSSA TSSWTLLHLA DRPDVVEALY QEQKQKLG--
Mglob51 SYKNGRNIND REIAHMMIAL LMAQQHTSSA TGSWAMLRLA SRPEIIEELY EEQKRVS--
Calb51  TYKGDVKMTD QEIANLLIGI LMGQQHTSAS TSAWFLHLHG EKPHLQDVIY QEVVELLK--
ClustalX  *** : * :*:*: : **.**:*: : * ** . : : : *

```

```

          370          380          390          400          410          420
      ....|....| ....|....| ....|....| .. SRS-5 ....|....| ....|....|
Af51B  DLP---PLT YDNLQ-KLDL HAKVIKETLR LHAPIHSIIR AVKNPMAVDG -----
Trub51  DLP---PLT YEALQ-KLDL HNNVIKETLR LHAPIHSILR AVKSPMPVEG -----
Mgram51 NADGSIKELT YANLS-KLTL LNQVVKETLR IHAPIHSILR KVKSPMPIEG -----
Af51A  GPDGSLPPLQ YKDLQ-KLPF HQHVIRETLR IHSSIHSIMR KVKSPMPVPG -----
Cneo51  NPDGTFRDYR YEDLK-ELPI MDSIIRETLR MHAPIHSIYR KVLSDIPVPP SLAP-----
Mglob51 DGTGGFAPLD YDIQSSVPV LDAVIRETLR LHPPIHSIMR KVKSDMVVPP TLAAPISSKG
Calb51  EKGDDLNDLT YEDLQ-KLPS VNNTIKETLR MHMPLHSIFR KVTNPLRIPE -----
ClustalX  * . : :**** :* .:*** * * . : :

```

```

          430          440          450          460          470          480
      ....|....| ....|....| ....|....| ....|....| ....|....|
Af51B  ---TSYVIPT SHNVLSSPGV TARSEEHPFN PLEWNPWRWD EN----- -IAASAEDD-
Trub51  ---TNYVVPT SHNLLAAPGV PSRDPQYFPD PLVWNPWRWE NN----- -VGVTVVEAS
Mgram51 ---TAYVIPT THTLAAPGT TSRMDEHPFD CLHWEPWRWD ESPSEKYKHL SPTTALGSIA
Af51A  ---TPYMIPP GRVLLASPGV TALSDEHPFN AGCWDPWRWE NQ----- ---ATKEQEN
Cneo51  SENGQYIIPK GHYVIAAPGV SQMDPRIWQD AKVWNPWRWH DEKG-----F AAAAMVQYTK
Mglob51 SRDETYVIPK GHYVIAAPGV SQVDPKIWED ASRFDWRWL GDK----- --ANVMNQTD
Calb51  ---TNYIVPK GHYVLVSPGY AHTSERYFDN PEDFDWRWD TAAA----- -KANSVSFNS
ClustalX  *:* : : :** . . : : :** **

```

```

          490          500          510          520          530          540
      ....|....| ....|....| Heme-Cys ....|....| ....|....|
Af51B  -EKVDYGYGL VSKGTNSPYL PFGAGRRHCI GEQFAYLQLG TITAVLVRLF RFRNLPG-VD
Trub51  EEKTDYGYGL VSKGANSPYL PFGSGRRHCI GEQFAYVQLG TVTATLARLM RWKQVEGTKD
Mgram51 EEKEDYGYGL VSKGAASPYL PFGAGRRHCI GEQFAYVQLQ TITATMVRDF KFYNDG-SD
Af51A  DKVVDYGYGA VSKGTSSPYL PFGAGRRHCI GEKFAYVNLG VILATIVRHL RLFNVDG-KK
Cneo51  AEQVDYGFSG VSKGTESPYQ PFGAGRRHCV GEQFAYTQLS TIFTYVVRNF TLKLAVP---
Mglob51 DAQEDFGWGM VSTGANSPYL PFGAGRRHCI GEQFAYLQLG TIISTFVRAF DWRLLET----
Calb51  SDEVDYGF GK VSKGVSSPYL PFGGRRHCI GEQFAYVQLG TILTTFVYNL RWTIDGY---
ClustalX  *:* **.* ** **.**: :*:** :* . : : . :

```

```

          550          560          570
      ....| SRS-6 ....| ....|....| ...
Af51B  GIPDTDYSSL FSKPLGRSFV EF EKRESATK A--
Trub51  VVPPTDYSSL FSKPFGNPMV SWEKRKQASQ K--
Mgram51 NVVGTDYSSL FSRPLSPAVV KWERRREEKEE KN-
Af51A  GVPETDYSSL FSGPMKPSII GWEKRKNTS K--
Cneo51  KFPETNYRTM IVQPNPL-V TFTLRNAEVK QEV
Mglob51 KLPAPDYISM VVLPTQPANL VFTPRKNKA- ---
Calb51  KVPDPDYISM VVLPTPEAEI IWEKRETCMF ---
ClustalX  . : * : : * : : *

```

**Supplementary figure S1.** Sequence alignment of selected fungal CYP51 enzymes. This alignment shows the six substrate recognition sites (SRS) according to Strushkevich et al (1) and the twenty-three conserved CYP51 amino acid residues (2) in orange as well as the conserved heme-binding cysteine residue in red. The fungal CYP51 sequences aligned were *Aspergillus fumigatus* CYP51 isoenzyme A (Af51A – UniProt accession number Q4WNT5), *Aspergillus fumigatus* CYP51 isoenzyme B (Af51B – Q96W81), *Candida albicans* CYP51 (Calb51 – P10613), *Cryptococcus neoformans* CYP51 (Cneo51 – Q5KQ65), *Malassezia globosa* CYP51 (Mglob51 – A8Q3I7), *Mycosphaerella graminicola* CYP51 (Mgram51 – Q5XWE5) and *Trichophyton rubrum* CYP51 (Trub51 – F2SHH3). ClustalX consensus sequence indicates absolutely conserved residues (\*), conserved strong (STA, NEQK, NHQK, NDEQ, QHRK, MILV, MILF, HY, FYW) groups (:), and conserved weaker (CSA, ATV, SAG, STNK, STPA, SGND, SNDEQK, NDEQHK, NEQHRK, FVLIM, HFY) groups (.) (<http://www.clustal.org>).

## REFERENCES

1. Strushkevich N, Usanov SA, Park HW. 2010. Structural basis of human CYP51 inhibition by antifungal azoles. *J Mol Biol* 397:1067-1078.
2. Lepesheva GI, Waterman MR. 2011. Structural basis for conservation in the CYP51 family. *Biochim Biophys Acta* 1814:88-93.